Ichnos Glenmark Innovation (IGI) has reported promising early clinical results for its investigational trispecific antibody ISB 2001 in treating relapsed or refractory multiple myeloma (RRMM).

The shares of Glenmark Pharmaceuticals Limited were trading at ₹1,553.90 up by ₹39.75 or 2.63 per cent on the NSE today at 11.05 am.

• Read also:IGI reports 75% response rate in multiple myeloma drug trial 

In a Phase 1 study presented at the 66th American Society of Hematology Annual Meeting, the drug demonstrated an overall response rate of 83 per cent among 18 patients treated at active doses. The study focused on heavily pretreated patients who had undergone a median of 6 prior lines of therapy.

The treatment showed a favorable safety profile, with no dose-limiting toxicities observed up to weekly subcutaneous doses of 1.2 mg/kg. Only mild cytokine release syndrome was reported, with no cases of neurotoxicity or treatment discontinuations due to adverse events.

• Read also: IGI reports 75% response rate in multiple myeloma drug trial

Key highlights include a 22 per cent complete response rate, with patients showing durable responses that deepened over time. The median time to first objective response was 36 days, and 80 per cent of patients remained on treatment at the data cutoff.

Developed using IGI’s proprietary BEAT protein platform, ISB 2001 targets BCMA and CD38 on myeloma cells and CD3 on T cells. The company plans to continue the study’s dose-expansion phase to establish the recommended Phase 2 dose and optimal dosing schedule.